Muutke küpsiste eelistusi

Group-Sequential Clinical Trials with Multiple Co-Objectives 1st ed. 2016 [Pehme köide]

  • Formaat: Paperback / softback, 113 pages, kõrgus x laius: 235x155 mm, kaal: 454 g, 14 Illustrations, black and white; IX, 113 p. 14 illus., 1 Paperback / softback
  • Sari: JSS Research Series in Statistics
  • Ilmumisaeg: 10-Jun-2016
  • Kirjastus: Springer Verlag, Japan
  • ISBN-10: 4431558985
  • ISBN-13: 9784431558989
Teised raamatud teemal:
  • Pehme köide
  • Hind: 62,59 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 73,64 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Paperback / softback, 113 pages, kõrgus x laius: 235x155 mm, kaal: 454 g, 14 Illustrations, black and white; IX, 113 p. 14 illus., 1 Paperback / softback
  • Sari: JSS Research Series in Statistics
  • Ilmumisaeg: 10-Jun-2016
  • Kirjastus: Springer Verlag, Japan
  • ISBN-10: 4431558985
  • ISBN-13: 9784431558989
Teised raamatud teemal:
This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control.

Arvustused

This book is a highly stimulating read for anyone who is interested in group-sequential trials, or anybody who wishes to learn about how studies with multiple endpoints can be made more efficient. (Michael J. Grayling, Technometrics, Vol. 60 (3), 2018)

1 Introduction
1(14)
1.1 Emerging Statistical Issues in Clinical Trials
1(8)
1.1.1 Multiple Co-primary Endpoints
2(2)
1.1.2 Non-inferiority
4(3)
1.1.3 Adaptive Designs
7(2)
1.2 Organization of the Book
9(6)
References
11(4)
2 Interim Evaluation of Efficacy in Clinical Trials with Two Co-primary Endpoints
15(26)
2.1 Introduction
15(1)
2.2 Continuous Outcomes
16(13)
2.2.1 Notation and Statistical Setting
16(1)
2.2.2 Decision-Making Frameworks and Stopping Rules
17(6)
2.2.3 Sample Sizes
23(3)
2.2.4 Illustration
26(3)
2.3 Binary Outcomes
29(5)
2.3.1 Notation and Statistical Setting
30(1)
2.3.2 Illustration
31(3)
2.4 Practical Issues
34(2)
2.5 Summary
36(5)
References
37(4)
3 Sample Size Recalculation in Clinical Trials with Two Co-primary Endpoints
41(10)
3.1 Sample Size Recalculation
41(1)
3.2 Test Statistics and Conditional Power
42(3)
3.3 Illustration
45(1)
3.4 Application to Binary Outcomes
46(3)
3.5 Summary
49(2)
References
49(2)
4 Interim Evaluation of Efficacy or Futility in Clinical Trials with Two Co-primary Endpoints
51(16)
4.1 Introduction
51(2)
4.2 Decision-Making Frameworks and Stopping Rules
53(6)
4.3 Illustration
59(4)
4.4 Summary
63(4)
References
64(3)
5 Interim Evaluation of Efficacy in Clinical Trials with Two Primary Endpoints
67(14)
5.1 Introduction
67(1)
5.2 Decision-Making Frameworks and Stopping Rules
68(8)
5.2.1 Notation and Statistical Setting
68(1)
5.2.2 Weighted Bonferroni Procedure
69(3)
5.2.3 Weighted Bonferroni Procedure with the Reallocated Significance Level
72(4)
5.3 Illustration
76(3)
5.4 Summary
79(2)
References
79(2)
6 Group-Sequential Three-Arm Non-inferiority Clinical Trials
81(16)
6.1 Introduction
81(3)
6.2 Evaluating Assay Sensitivity and Non-inferiority
84(2)
6.2.1 Notation and Statistical Setting
84(1)
6.2.2 The Fixed Margin Approach
84(1)
6.2.3 The Fraction Approach
85(1)
6.3 Decision-Making Frameworks and Stopping Rules
86(3)
6.4 Illustration
89(3)
6.5 Summary
92(5)
References
93(4)
7 Future Developments
97(6)
7.1 Introduction
97(1)
7.2 Multiple Intervention Arms
98(1)
7.3 Multiple Event-Time Outcomes
98(1)
7.4 Endpoint Selection Designs
99(1)
7.5 Enrichment Designs and Subgroup Analyses
99(4)
References
101(2)
Appendix A Calculation of Power and Conditional Power in Group-Sequential Clinical Trials with Two Co-primary Endpoints 103(4)
Appendix B Efficacy and Futility Critical Boundaries and Sample Size Calculation in Group-Sequential Clinical Trials with Two Co-primary Endpoints 107(2)
Appendix C ASN Calculations in Group-Sequential Clinical Trials Including Efficacy and Futility Assessments 109(2)
Appendix D ASN Calculations in Three-Arm Group-Sequential Clinical Trials 111
Toshimitsu Hamasaki, Professor, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan Koko Asakura, Research Assistant, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan Scott Richard Evans, Senior Research Scientist, Harvard School of Public Health, 651 Huntington Avenue, Boston, Massachusetts 02115, USAToshimitsu Ochiai, Biostatistics Department, Shionogi & Co., Ltd., Japan